Skip to main content

Table 3 Clinical benefit

From: DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma

Docetaxel/Oxaliplatin (n = 44)

 

Number of Patients

Percent

95 % CI

Clinical benefit response

5

11.4

3.79–24.56

Pain intensity (n = 41)

   

 Decreased

4

9.8

2.72–23.13

 Stable

29

70.7

54.46–83.87

 Improved

8

19.5

8.82–34.87

Karnofsky Perfomance Score

   

 Decreased

16

36.4

22.41–52.23

 Stable

28

63.6

47.77–77.59

Body weight

   

 Decreased

40

90.9

78.33–97.47

 Increased

4

9.1

2.53–21.67

  1. 95 % CI confidence interval